JPRN-jRCT2080222290已完成1 期
A phase 1 clinical study of WT2725 in patients with advanced solid malignancies.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 8
研究概览
简要总结
This study was conducted to assess the safety of WT2725 in patients with advanced solid tumors, to determine MTDs, and to exploratory evaluate efficacy and biomarkers. No DLT was observed in any of the cohorts, and due to a change in the development plan, three additional patients were added to Cohort 2, and the MTD could not be determined because they were not evaluated in six patients.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •out-patient
- •Main Inclusion criteria
- •- Patients >= 20 year old at informed consent
- •- ECOG performance status: 0 or 1
- •- Histologically or cytologically diagnosed as solid tumor
- •- Refractory to standard treatment or no standard treatment is established
排除标准
- •Main Exclusion criteria
- •- Positive for HIV and HCV antibody, HBV surface antigen within 90 days prior to enrollment
- •- Symptomatic brain metastasis
- •- Previous treatment with WT2725 or WT1 peptide
研究者
相似试验
已完成
1 期
Clinical Study of WT2725 in Patients With Advanced MalignanciesCancerNCT01621542Sumitomo Pharma America, Inc.64
招募中
1 期
A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT04947033I-Mab Biopharma US Limited25
已完成
1 期
A Phase I study of WT4869 in patients with advanced solid malignanciesJPRN-jRCT2080221527Chugai Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma. Co., Ltd.25
终止
1 期
Dose-escalation Study of APG-1387 and Toripalimab in Solid TumorsAdvanced Solid TumorNCT04284488Ascentage Pharma Group Inc.40
已完成
1 期
A Study for Participants With Advanced CancerAdvanced CancerMetastatic CancerNCT01214629Eli Lilly and Company54